A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’” - Quiz - MDSpire

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

  • By

  • Matthias Augustin

  • April W. Armstrong

  • Naiem T. Issa

  • Anne Sohrt Petersen

  • Rie von Eyben

  • Teodora Festini

  • Tiago Torres

  • June 26, 2026

  • 0 min

Share

Original Source(s)

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

  • by Matthias Augustin, April W. Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres

  • June 26, 2026

Related Content

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes